Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 18.4% in the morning session after the company reported second-quarter earnings and revenue that surpassed analyst estimates and raised its full-year financial guidance. The specialty pharmaceutical company announced quarterly net revenues of $211.4 million, a 53.1% year-over-year increase that beat analyst estimates of $191.5 million. Adjusted earnings per share came in at $1.80, also significantly higher than the consensus forecast of $1.42. Bolstering investor confidence, ANI Pharmaceuticals increased its 2025 forecast, now expecting full-year revenues between $818 million and $843 million and adjusted earnings per share from $6.98 to $7.35, both well above prior guidance.

Is now the time to buy ANI Pharmaceuticals? Access our full analysis report here, it’s free.

ANI Pharmaceuticals’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for ANI Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 5 months ago when the stock gained 13.4% on the news that the company reported strong fourth-quarter 2024 results, significantly surpassing analysts' revenue expectations. Revenue surged 45% year-on-year, fueled by continued growth in its Rare Disease segment. Purified Cortrophin Gel led the way with a 42% rise, while the newly added ILUVIEN and YUTIQ products also boosted sales. The company raised its 2025 outlook, expecting sales to climb up to 26% and earnings per share to grow as much as 25%. Overall, the quarter showed strong sales growth and smart investments.

ANI Pharmaceuticals is up 49.3% since the beginning of the year, and at $82.78 per share, has set a new 52-week high. Investors who bought $1,000 worth of ANI Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $2,503.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.